Cargando…
Prescribing cannabis for harm reduction
Neuropathic pain affects between 5% and 10% of the US population and can be refractory to treatment. Opioids may be recommended as a second-line pharmacotherapy but have risks including overdose and death. Cannabis has been shown to be effective for treating nerve pain without the risk of fatal pois...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295721/ https://www.ncbi.nlm.nih.gov/pubmed/22208773 http://dx.doi.org/10.1186/1477-7517-9-1 |
_version_ | 1782225628126248960 |
---|---|
author | Collen, Mark |
author_facet | Collen, Mark |
author_sort | Collen, Mark |
collection | PubMed |
description | Neuropathic pain affects between 5% and 10% of the US population and can be refractory to treatment. Opioids may be recommended as a second-line pharmacotherapy but have risks including overdose and death. Cannabis has been shown to be effective for treating nerve pain without the risk of fatal poisoning. The author suggests that physicians who treat neuropathic pain with opioids should evaluate their patients for a trial of cannabis and prescribe it when appropriate prior to using opioids. This harm reduction strategy may reduce the morbidity and mortality rates associated with prescription pain medications. |
format | Online Article Text |
id | pubmed-3295721 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32957212012-03-07 Prescribing cannabis for harm reduction Collen, Mark Harm Reduct J Commentary Neuropathic pain affects between 5% and 10% of the US population and can be refractory to treatment. Opioids may be recommended as a second-line pharmacotherapy but have risks including overdose and death. Cannabis has been shown to be effective for treating nerve pain without the risk of fatal poisoning. The author suggests that physicians who treat neuropathic pain with opioids should evaluate their patients for a trial of cannabis and prescribe it when appropriate prior to using opioids. This harm reduction strategy may reduce the morbidity and mortality rates associated with prescription pain medications. BioMed Central 2012-01-01 /pmc/articles/PMC3295721/ /pubmed/22208773 http://dx.doi.org/10.1186/1477-7517-9-1 Text en Copyright ©2012 Collen; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentary Collen, Mark Prescribing cannabis for harm reduction |
title | Prescribing cannabis for harm reduction |
title_full | Prescribing cannabis for harm reduction |
title_fullStr | Prescribing cannabis for harm reduction |
title_full_unstemmed | Prescribing cannabis for harm reduction |
title_short | Prescribing cannabis for harm reduction |
title_sort | prescribing cannabis for harm reduction |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295721/ https://www.ncbi.nlm.nih.gov/pubmed/22208773 http://dx.doi.org/10.1186/1477-7517-9-1 |
work_keys_str_mv | AT collenmark prescribingcannabisforharmreduction |